Cantor Fitzgerald Issues Negative Estimate for PTCT Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for PTC Therapeutics in a report issued on Monday, February 3rd. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will post earnings per share of ($3.26) for the year, down from their previous forecast of ($2.84). Cantor Fitzgerald currently has a “Overweight” rating and a $113.00 target price on the stock. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.56) per share.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.15. The company had revenue of $196.79 million during the quarter, compared to analysts’ expectations of $173.51 million. During the same quarter last year, the business posted ($1.76) earnings per share.

PTCT has been the topic of a number of other reports. Barclays raised their price target on PTC Therapeutics from $45.00 to $56.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 3rd. Robert W. Baird lifted their target price on PTC Therapeutics from $52.00 to $70.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 3rd. Morgan Stanley upgraded PTC Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $45.00 to $67.00 in a research report on Friday, December 13th. Royal Bank of Canada upgraded PTC Therapeutics from a “sector perform” rating to an “outperform” rating and lifted their target price for the stock from $39.00 to $63.00 in a research report on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. lifted their target price on PTC Therapeutics from $51.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 19th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, PTC Therapeutics has a consensus rating of “Hold” and an average price target of $57.85.

PTC Therapeutics Stock Performance

PTC Therapeutics stock opened at $49.38 on Wednesday. PTC Therapeutics has a 1-year low of $23.58 and a 1-year high of $54.16. The stock’s fifty day moving average is $46.14 and its two-hundred day moving average is $40.05.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. grew its position in PTC Therapeutics by 7.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 706,730 shares of the biopharmaceutical company’s stock worth $26,220,000 after buying an additional 47,902 shares during the last quarter. Two Sigma Advisers LP grew its position in PTC Therapeutics by 10.3% during the 3rd quarter. Two Sigma Advisers LP now owns 429,842 shares of the biopharmaceutical company’s stock worth $15,947,000 after purchasing an additional 40,300 shares in the last quarter. Intech Investment Management LLC purchased a new position in PTC Therapeutics during the 3rd quarter worth approximately $698,000. Quest Partners LLC grew its position in PTC Therapeutics by 433.9% during the 3rd quarter. Quest Partners LLC now owns 22,359 shares of the biopharmaceutical company’s stock worth $830,000 after purchasing an additional 18,171 shares in the last quarter. Finally, State Street Corp grew its position in PTC Therapeutics by 5.4% during the 3rd quarter. State Street Corp now owns 2,899,040 shares of the biopharmaceutical company’s stock worth $107,554,000 after purchasing an additional 149,700 shares in the last quarter.

Insider Activity

In related news, insider Neil Gregory Almstead sold 69,550 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $52.06, for a total transaction of $3,620,773.00. Following the sale, the insider now owns 86,202 shares of the company’s stock, valued at $4,487,676.12. The trade was a 44.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Mark Elliott Boulding sold 85,600 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $52.26, for a total value of $4,473,456.00. Following the sale, the vice president now directly owns 92,389 shares in the company, valued at approximately $4,828,249.14. The trade was a 48.09 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 211,737 shares of company stock valued at $10,920,687. Insiders own 5.50% of the company’s stock.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.